Avidicure CEO Arthur Lahr spoke with Nuala Moran of BioWorld News about their $50M seed funding and how AVC-Boosters are designed to activate multiple immune pathways, unlocking powerful responses across both the innate and adaptive immune system. Read the full...
AVC-Boosters are designed as dual agonistic antibodies to safely deliver targeted and potentmonotherapy with broad application in oncology Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other cancer...
Cincinnati, Ohio, US and Eindhoven, Netherlands – February 27, 2025 – Sirius Medical, the innovator of Surgical Marker Navigation and Mammotome, a globally recognized leader in breast care, are proud to announce an exclusive distribution agreement for the United...
Eindhoven, the Netherlands – 4 February 2025 – As World Cancer Day is observed, Dutch medical device company Sirius Medical, the leader in surgical marker navigation, announced securing 10M€ in additional scale-up funding. This investment round was led by...
TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today’s standard of care – saving lives and reducing disability Following the Phase 1 safety study, TargED intends to further develop TGD001 in...
Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and Novartis Venture Fund Lead first-in-class product candidate, monoclonal antibody CIT-013, to be advanced into two Phase 2a studies Oss, Netherlands – 09 December 2024 – Citryll, a biotech...
